IM is a tyrosine kinase inhibitor in use for the clinical management of chronic myeloid leukemia and has been shown to inhibit several different kinases, including CSF-1R. The gene discussed is CSF1R; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.